Associate Professor Megan Crumbaker

Conjoint Associate Professor

Medicine & Health

School of Clinical Medicine

Dr Crumbaker is medical oncologist specialising in genito-urinary (GU) cancers the Kinghorn Cancer Centre and St. Vincent’s, Sydney where she leads the GU clinical trials portfolio. She is committed to conducting high quality clinical research with special interests in circulating and imaging biomarkers and radioligand therapies in prostate cancer.

Phone

+61-2-9355 5655

Journal articles | 2025

Crumbaker M; Krieger L; Pook DW; Davis ID; Fontela A; Oldmeadow C; Hurwitz J; Inderjeeth AJ; Dhillon HM; Downton T; Marx GM; Shekar S; Antonarakis ES; Denmeade SR; Anton A; Tan TH; Sharma S; Goh JC; Horvath L; Joshua AM, 2025, 'Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.tps298

Journal articles | 2025

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218

Journal articles | 2025

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Sandhu S; Zhang AY; Hofman MS; Thomas H; Martin AJ; Davis ID; Stockler MR, 2025, 'Overall survival and quality of life with [ ¹⁷⁷ Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).', Journal of Clinical Oncology, 43, pp. 17 - 17, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.17

Journal articles | 2025

Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura K; Kollmannsberger CK; Crumbaker M; Lalani AKA; Powles T; Ebrahimi H; McKay RR; Lee JL; Kanesvaran R; Choueiri TK; Heng DYC, 2025, 'Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis', European urology oncology, 8, pp. 171 - 178, http://dx.doi.org/10.1016/j.euo.2024.12.011

Journal articles | 2025

Kostos L; Buteau JP; Kong G; Tran B; Haskali MB; Fahey M; Crumbaker M; Emmett L; Hofman MS; Azad AA, 2025, 'Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [¹⁷⁷Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer', Journal of Nuclear Medicine, 66, pp. 572 - 578, http://dx.doi.org/10.2967/jnumed.124.269252

Journal articles | 2025

Lin KL; Shekar S; Crumbaker M; Joshua AM, 2025, 'Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men', New England Journal of Medicine, 392, pp. 202 - 203, http://dx.doi.org/10.1056/NEJMc2412361

Journal articles | 2025

Zarba M; O'Sullivan D; El Hajj Chehade R; McKay RR; Pal SK; Beuselinck B; Donskov F; Lalani A-KA; Crumbaker M; Li H; Alva AS; Powles T; Takemura K; Kollmannsberger CK; Wong SS; Wood LA; de Velasco G; Cheung WY; Choueiri TK; Heng DYC, 2025, 'Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).', Journal of Clinical Oncology, 43, pp. 479 - 479, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.479

Journal articles | 2024

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', The Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Journal articles | 2024

Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura KN; Kollmannsberger CK; Crumbaker M; Lalani A-KA; Powles T; Pal SK; McKay RR; Lee J-L; Kanesvaran R; Choueiri TK; Heng DYC, 2024, 'Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.', Journal of Clinical Oncology, 42, pp. 390 - 390, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.390

Journal articles | 2024

Hall A; Crumbaker M; Pham J; Liu JJ; Sim H-W; Joshua AM, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', Journal of Clinical Oncology, 42, pp. 4 - 4, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.4

Journal articles | 2024

Kumar S; Crumbaker M; Emmett L, 2024, '“Unraveling the Hypocalcemic Response to ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy,”', Journal of Nuclear Medicine, 65, pp. 333 - 334, http://dx.doi.org/10.2967/jnumed.123.266768

Journal articles | 2024

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of ⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on ⁶⁸Ga-PSMA-11 PET/CT', Journal of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Journal articles | 2024

Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L, 2024, 'Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to ¹⁷⁷Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes', Journal of Nuclear Medicine, 65, pp. 904 - 908, http://dx.doi.org/10.2967/jnumed.123.267014

Journal articles | 2024

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.', J Nucl Med, http://dx.doi.org/10.2967/jnumed.124.267606

Journal articles | 2024

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. S975 - S976, http://dx.doi.org/10.1016/j.annonc.2024.08.1697

Journal articles | 2023

Conduit C; Mak B; Qu W; Yeung T; Bressel M; Cusick T; Dhillon HM; De Abreu Lourenço R; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Sewak S; Chau NMH; Allen R; Davis ID; Clark SJ; Horvath L; Mahon KL, 2023, 'GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).', Journal of Clinical Oncology, 41, pp. TPS5099 - TPS5099, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5099

Journal articles | 2023

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Journal articles | 2023

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392

Journal articles | 2023

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Pattison DA; Tan H; Kirkwood ID; Sandhu SK; Nguyen A; Gedye C; Rutherford N; Hofman M; Martin A; Stockler MR; Davis ID, 2023, 'Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', ANNALS OF ONCOLOGY, 34, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086

Journal articles | 2023

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; Pasam A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, 'Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', ANNALS OF ONCOLOGY, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773

Journal articles | 2023

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Journal articles | 2023

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Journal articles | 2023

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy', Journal of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Journal articles | 2023

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of ¹⁷⁷Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

Journal articles | 2023

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Journal articles | 2023

Pemberton L; Allen C; Handel E; Weickhardt AJ; Tran B; Crumbaker M; Shapiro JD; Risbridger GP; Pook DW, 2023, 'Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).', Journal of Clinical Oncology, 41, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.158

Journal articles | 2023

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Journal articles | 2022

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Lau H; Woo H; Bariol S; Gurney H, 2022, 'Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center', Asia-Pacific Journal of Clinical Oncology, 18, pp. e23 - e31, http://dx.doi.org/10.1111/ajco.13548

Journal articles | 2022

Chan DL; Pavlakis N; Crumbaker M; Lawrence B; Barber C; Price TJ; Michael M; Oberg K, 2022, 'Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series', Asia-Pacific Journal of Clinical Oncology, 18, pp. 209 - 216, http://dx.doi.org/10.1111/ajco.13577

Journal articles | 2022

Chen S; Petricca J; Ye W; Guan J; Zeng Y; Cheng N; Gong L; Shen SY; Hua JT; Crumbaker M; Fraser M; Liu S; Bratman SV; van der Kwast T; Pugh T; Joshua AM; De Carvalho DD; Chi KN; Awadalla P; Ji G; Feng F; Wyatt AW; He HH, 2022, 'The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-34012-2

Journal articles | 2022

Conduit C; Mak B; Qu W; Lulio JD; Burder R; Bressel M; Cusick T; Dhillon HM; Lourenço RDA; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Allen R; Davis ID; Clark SJ; Horvath LG; Mahon KL, 2022, 'GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221092486

Journal articles | 2022

Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM, 2022, 'Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER', European Journal of Cancer, 170, pp. 285 - 295, http://dx.doi.org/10.1016/j.ejca.2022.04.005

Journal articles | 2022

Joshua AM; Gurney H; Dhillon HM; Crumbaker M, 2022, 'Patient Preference or Indifference: Learning from the CABADOC Study', European Urology, 81, pp. 241 - 242, http://dx.doi.org/10.1016/j.eururo.2021.11.005

Journal articles | 2022

Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG, 2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0

Journal articles | 2022

Nguyen LT; Lo CS; Fyrsta M; Nie J; Yam JY; Yen PH; Le MX; Hersey K; Kenk M; Crumbaker M; Fleshner N; Kulkarni G; Hamilton R; Jewett M; Finelli A; Evans A; Sweet J; Ohashi PS; Joshua AM, 2022, 'Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue', Prostate Cancer, 2022, http://dx.doi.org/10.1155/2022/6499344

Journal articles | 2022

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Journal articles | 2021

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of ¹⁷⁷Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Journal articles | 2021

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

Journal articles | 2021

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10, http://dx.doi.org/10.21037/tau-20-1444

Journal articles | 2021

Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625

Journal articles | 2021

Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964

Journal articles | 2020

Bhatnagar A; McKay MJ; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2020, 'Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma', Journal of Mass Spectrometry, 55, http://dx.doi.org/10.1002/jms.4584

Journal articles | 2020

Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM, 2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, 12, http://dx.doi.org/10.3390/cancers12051178

Journal articles | 2020

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Journal articles | 2020

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Journal articles | 2020

Quah GT; Espinoza D; Arasaratnam M; Crumbaker M; Balakrishnar B; Brooks A; Lau H; Patel M; Bariol S; Gurney H, 2020, '212P Stage I non-seminoma testicular cancer: Adjuvant management and outcomes', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.223

Journal articles | 2020

Quah GT; Espinoza D; Crumbaker M; Balakrishnar B; Arasaratnam M; Bariol S; Brooks A; Lau H; Patel M; Gurney H, 2020, '213P Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.224

Journal articles | 2019

Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H, 2019, 'Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer', Cancer Chemotherapy and Pharmacology, 84, pp. 139 - 146, http://dx.doi.org/10.1007/s00280-019-03862-x

Journal articles | 2019

Bhatnagar A; McKay MJ; Thaysen-Andersen M; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2019, 'Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121741

Journal articles | 2019

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Journal articles | 2019

Crumbaker M; Wong J; Joshua AM; Spigelman AD, 2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia-Pacific Journal of Clinical Oncology, 15, pp. 257 - 261, http://dx.doi.org/10.1111/ajco.13148

Journal articles | 2019

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Journal articles | 2019

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Journal articles | 2018

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden A; Brooks A; Patel M; Gurney H, 2018, 'Patterns of care and outcome of germ cell tumours (GCT) in an Australian high-volume centre.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16534

Journal articles | 2018

Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP, 2018, 'Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry', Journal of Pharmaceutical and Biomedical Analysis, 154, pp. 66 - 74, http://dx.doi.org/10.1016/j.jpba.2018.03.012

Journal articles | 2018

Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N, 2018, 'Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia', Asia-Pacific Journal of Clinical Oncology, 14, pp. e45 - e49, http://dx.doi.org/10.1111/ajco.12686

Journal articles | 2018

Crumbaker M; Savdie R; Joshua AM, 2018, 'Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer', European Urology, 73, pp. 736 - 737, http://dx.doi.org/10.1016/j.eururo.2017.11.005

Journal articles | 2017

Crumbaker M; Gurney H, 2017, 'Dose considerations for anti-cancer drugs in metastatic prostate cancer', Prostate, 77, pp. 1199 - 1204, http://dx.doi.org/10.1002/pros.23378

Journal articles | 2017

Crumbaker M; Khoja L; Joshua AM, 2017, 'AR signaling and the PI3K pathway in prostate cancer', Cancers, 9, pp. 34, http://dx.doi.org/10.3390/cancers9040034

Journal articles | 2017

Mersiades A; Crumbaker M; Gao B; Nagrial A; Hui R, 2017, 'P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, 12, pp. S1293 - S1293, http://dx.doi.org/10.1016/j.jtho.2016.11.1828

Journal articles | 2016

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, pp. ix151 - ix151, http://dx.doi.org/10.1016/s0923-7534(21)00629-3

Journal articles | 2016

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw594.035

Journal articles | 2015

Chan D; McLachlan JM; Crumbaker M; Marx GM, 2015, 'Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.273

Journal articles | 2015

McLachlan JM; Chan DL; Crumbaker MA; Marx GM, 2015, 'Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer', Cancer Treatment Communications, 4, pp. 81 - 85, http://dx.doi.org/10.1016/j.ctrc.2015.06.001
Conference Abstracts | 2024

Hall A; Crumbaker M; Pham J; Liu JJ; Sim H-W; Joshua AM, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 42, pp. 4 - 4, presented at American-Society-of-Clinical-Oncology: Genitourinary Cancers Symposium (ASCO GU), CA, San Francisco, 25 January 2024 - 27 January 2024, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.4

Conference Presentations | 2024

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer', presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CANADA, Toronto, 08 June 2024 - 11 June 2024, https://jnm.snmjournals.org/content/65/supplement_2/242460

Conference Papers | 2023

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Agrawal S; Poole A; Eu P; Crumbaker M; Chan L; Nguyen A, 2023, 'Patient outcomes following a response biomarker guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate resistant prostate cancer (Re-SPECT)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, INDIA, Jodhpur, presented at 55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON), INDIA, Jodhpur, 16 November 2023 - 19 November 2023

Conference Abstracts | 2022

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS205

Conference Abstracts | 2022

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Conference Abstracts | 2022

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Conference Abstracts | 2022

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Conference Abstracts | 2021

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS177

Conference Abstracts | 2021

Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.114

Conference Abstracts | 2021

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103

Conference Abstracts | 2021

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

Conference Papers | 2020

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Ardolino L; Tang R; Pathmanandavel S; Crumbaker M; Joshua A; Emmett L, 2019, 'Lu-177-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Chen J; Joshua AM; Denmeade SR; Antonarakis ES; Crumbaker M, 2019, 'High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS5095

Conference Abstracts | 2019

Emmett L; Crumbaker M; Nguyen A; Ho B; Yin C; Isheish N; Azad A; Violet J; Sharma S; Joshua A, 2019, 'Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800464&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Gurney H, 2018, 'Patterns of Care and Outcome of Germ Cell Tumours (GCT) in an Australian High-Volume Centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 28 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437670700015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Crumbaker M; Joshua AM; Epstein R; Emmett L, 2018, 'A phase I study of ¹⁷⁷Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5088

Conference Papers | 2015

Itchins M; Sinn K; Chan D; Crumbaker M; Gill A; Clarke S; Pavlakis N, 2015, 'ALK TRANSLOCATED NON-SMALL CELL LUNG CANCER: EXPERIENCE FROM AN AUSTRALIAN METROPOLITAN TERTIARY REFERRAL CENTRE', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 174 - 175, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Follow

Associate Professor Megan Crumbaker